You are here

New Drug Application Submitted to FDA for Fixed-Dose Atazanavir/Cobicistat Combo for HIV-1 Patients

Treatment eliminates need for boosting agent in separate tablet

A new drug application (NDA) has been submitted to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz (Bristol-Myers Squibb), and cobicistat (Gilead Sciences), an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain human immunodeficiency virus-1 (HIV-1) medications in the blood and make them more effective.

Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat would offer patients with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet.

Reyataz (atazanavir sulfate) is currently indicated in combination with other antiretroviral agents for the once-daily treatment of HIV-1 infection. This is based on analyses of plasma HIV-1 RNA levels and CD4-positive cell counts from controlled studies of 96 weeks (treatment- naïve) and 48 weeks (treatment-experienced) duration in adult and pediatric patients at least 6 years of age.

Approximately 245,000 patients in the U.S. have been treated with Reyataz since its launch in 2003 — nearly twice that of other protease inhibitors launched since that time. Reyataz is currently used in combination with other antiretroviral agents and is most commonly used with ritonavir, a pharmacokinetic enhancer.

Atazanavir sulfate is the only protease inhibitor that has been evaluated with cobicistat in a prospective, randomized, phase III double-blind clinical trial, which compared the efficacy and safety of cobicistat-boosted atazanavir sulfate with that of ritonavir-boosted atazanavir sulfate in treatment-naïve adults for 48 weeks.

In October 2011, Bristol-Myers Squibb announced a licensing agreement with Gilead for the development and commercialization of a once-daily, single-tablet, fixed-dose combination product of atazanavir sulfate and Gilead’s cobicistat.

Source: Bristol-Myers Squibb; April 14, 2014.

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut